choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Ampyra

Ampyra Newsletter
  • Acorda loses Nasdaq listing to cap biotech’s end 16 Apr 2024 16:27 GMT

    … twilight zone. The biotech’s closure date is … drugs for neurological disorders. Inbrija (levodopa inhalation powder) and Ampyra … ability of patients with multiple sclerosis. According to GlobalData’s … the parent company of Pharmaceutical Technology. Access the …

  • Acorda seeks buyer as neurological drug sales fall 05 Apr 2024 00:30 GMT

    … of the year. Merz Pharmaceuticals, of Frankfurt, German, … founded in 1995 by medical doctor Ron Cohen. It is … developed medicines that treat Parkinson’s disease and multiple sclerosis. Ampyra, also … drug was undergoing clinical trials. The U.S. Food and Drug …

  • Essential drugmaker to sell, liquidate in Chapter 11 bankruptcy 04 Apr 2024 07:39 GMT

    … markets its Ampyra drug, which improves walking in adults with multiple sclerosis. The … the Food and Drug Administration for intermittent treatment of episodic … drug under contract through 2030. Biotech technician working in a lab.Shutterstock Pharmaceutical …

  • Acorda Joins Growing Group of Biotechs Filing for Bankruptcy, Divests Assets to Merz 03 Apr 2024 12:43 GMT

    … asset purchase agreement with German biotech Merz Therapeutics, which has … , including its FDA-approved drugs Inbrija (levodopa inhalation powder), Ampyra (dalfampiridine) and … supply of our medications to people with multiple sclerosis and Parkinson’s …

  • 3 Biotech Stocks to Watch in March for Success 28 Feb 2024 22:34 GMT

    … for high-quality treatments for both rare … trials. A survey by ICON plc, involving more than 130 biotech … Ampyra, an oral drug designed to improve walking in adults with multiple sclerosis … and commercializes pharmaceutical products for unmet medical needs in …

  • Amid Declining Sales, Biogen Hands MS Drug Fampyra Back to Acorda 12 Jan 2024 16:19 GMT

    … turning its back on its multiple sclerosis agreement with Acorda Therapeutics, … still incompletely known. The drug is thought to act on … neurons. The drug was approved by the FDA in January 2010 … of 2023, the biotech reported that Ampyra’s revenue had declined …

  • Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda 11 Jan 2024 23:05 GMT

    … sales declining for aging multiple sclerosis (MS) drug Fampyra, Biogen has exercised … access to this important medication for people with MS … U.S. revenue for Ampyra—its commercial name in the … its Parkinson’s disease treatment Inbrija never materialized. The …

  • 3 Biotech Stocks Flashing Year-End 'Buy' Signals" 15 Dec 2023 13:07 GMT

    … standardize clinical trials. The FDA approved more than 50 new drugs in … biotechnology market is expanding rapidly due to rising demand for personalized medicine … Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis …

  • 3 Safe Biotech Stocks to Buy This Week 24 Nov 2023 15:33 GMT

    … among biotech and pharmaceutical companies to prepare and manufacture vaccines. The … for personalized medicine and treatment, propelling the biotech industry’s … Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis …

  • Acorda filed for bankruptcy, and Merz is eyeing its assets 02 Apr 2024 13:30 GMT

    … the table are Acorda’s multiple sclerosis therapy Ampyra/Fampyra (dalfampridine) and … some growth over that period, Ampyra has gone into a steady … uninterrupted supply of our medications to people with multiple sclerosis and Parkinson’s …

Satisfied with the content?

Continue to create your account.